Ironwood Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ironwood Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Ironwood Pharmaceuticals inc achieved a return on average assets (ROA) of 34.51 % in its second quarter of 2026, this is above IRWD's average return on assets of -22.17%.
Ironwood Pharmaceuticals Inc assets over the 12 months ending in its second quarter of 2026 are valued at $376 million

ROA has improved compared to 26.29% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 29 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 154, from total ROA ranking in the first quarter of 2026 at 1102.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-14.67 %	36.44 %	16.49 %	2.45 %	-13.1 %
Y / Y Net Income Change	117.34 %	-	-	999.29 %	-
Net Income (TTM) in million	130	102	24	29	-8
Return On Assets (TTM)	34.51 %	26.29 %	6.68 %	8.26 %	-2.3 %
IRWD's Total Ranking	# 154	# 1102	# 765	# 2836	# 3269
Total Assets (TTM) in million	285	435	397	389	334
Seq. Total Assets Change	-34.39 %	9.49 %	2.1 %	16.35 %	4.91 %
Seq. Net Income Change	25.8 %	-	-	69.84 %	-

IRWD's 5 Years Annual ROA >> Back to IRWD Management Effectiveness >> Compare IRWD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 17
Sector	# 30
Overall	# 108

Return On Assets Statistics
High	Average	Low
76.57 %	-22.17 %	-212.34 %
(Jun 30 2021)		(Mar 31 2024)

Financial Statements
Ironwood Pharmaceuticals Inc 's Assets	$ 285 million	IRWD's Balance sheet
Ironwood Pharmaceuticals Inc 's Income	$ 51 million	Quarterly IRWD's Income Statement
IRWD's Income by Division		See IRWD's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	16.49 %	-26.02 %	-57.65 %	-27.52 %	175.18 %
Total Assets in million	397	341	461	1,088	1,500
Y / Y Net Income Change	2629.2 %	-	-	-66.87 %	397.71 %
Net Income in million	24	1	-1,032	175	528
Annual Return On Assets	6.05 %	0.26 %	-223.98 %	16.1 %	35.22 %

IRWD's 5 Years Annual ROA >> Back to IRWD Management Effectiveness >> Compare IRWD ROA to its Competitors

Comment on IRWD's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 6.05 % compared to prior year, due to annual net income growth of 2629.2 % to $24.02 million, while value of Ironwood Pharmaceuticals Inc 's overall assets grew just by 16.49 % to $396.90 million, compared to $396.90 a year before.

More Return On Assets Ratios
IRWD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IRWD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IRWD's Competitors
Subscribers only: Roa for Ironwood Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for IRWD's Customers

You may also want to know
IRWD's Roi	IRWD's Inventory Turnover Ratio	IRWD's Growth Rates	IRWD's Dividend Comparisons
	IRWD's Profitability Ratios	IRWD's Asset Turnover Ratio	IRWD's Dividend Growth
IRWD's Roe	IRWD's Valuation Ratios	IRWD's Financial Strength Ratios	IRWD's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %

Date modified: 2026-09-08T13:52:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.